Another failed prediction: MannKind’s Afrezza Likely to Fail AFFINITY 1 Phase III Trial
Another failed prediction, this one from Brian Wilson, lead contributor at BioMedReports April 2013:
Study 009 suggested that technosphere insulin (Afrezza) has inferior efficacy versus placebo. It is very likely that data from Affinity 1 will have the same end result, which would prevent Afrezza from receiving FDA approval. Since Afrezza seems to be the primary constituent of MannKind’s valuation, the stock should see a drastic revaluation to the downside once this is realized.